Sheets Smith Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Sheets Smith Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$660K	Buy	+16,992	New	+$552K	0.43%	70

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sheets Smith Investment Management's KNSA Position: Q3 2025 in Review

Sheets Smith Investment Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2025: 16,992 shares worth $660K. The stake represents 0.43% of the portfolio and ranks #70 among its holdings.

204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

Sheets Smith Investment Management held 16,992 shares of Kiniksa Pharmaceuticals worth $660K as of Q3 2025.
Kiniksa Pharmaceuticals was a new Sheets Smith Investment Management position in Q3 2025.
Kiniksa Pharmaceuticals made up 0.43% of Sheets Smith Investment Management's portfolio in Q3 2025, its #70 holding.
204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Sheets Smith Investment Management's 13F filing for Q3 2025, filed 8 Oct 2025.